18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy Meeting Abstract


Authors: D'Angelo, S. P.; Russell, J. S.; Bhatia, S.; Hamid, O.; Mehnert, J. M.; Terheyden, P.; Shih, K. C.; Brownell, I.; Lebbé, C.; Lewis, K. D.; Linette, G. P.; Milella, M.; Hennessy, M.; Bajars, M.; Zwiener, I.; Nghiem, P.
Abstract Title: 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy
Meeting Title: 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 5 Suppl.
Meeting Dates: 2018 Jan 25-27
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-10
Language: English
ACCESSION: WOS:000436177700183
DOI: 10.1200/JCO.2018.36.5_suppl.192
PROVIDER: wos
Notes: Meeting Abstract: 192 -- Source: Wos
Altmetric Score
MSK Authors
Related MSK Work